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fetus. Although HLA-G expression is restricted in normal tissues, it is broadly expressed in malignant tumors
andmay favor tumor immune escape.We analyzedHLA-G protein andmRNAexpression in tumor samples from
patients with glioblastoma collected in France, Denmark, andBrazil. We foundHLA-G protein expression in 65
of 108 samples and mRNA in 20 of 21 samples. The absence of HLA-G protein expression was associated with
a better long-term survival rate. The mechanisms underlying HLA-G gene expression were investigated in
glioma cell lines U251MG, D247MG, and U138MG. Induction of HLA-G transcriptional activity was dependent
of 5-aza-20-deoxycytidine treatment and enhanced by interferon-g. HLA-G protein expression was observed
in U251MG cells only. These cells exhibited a permissive chromatin state at the HLA-G gene promoter and the
highest levels of induced HLA-G transcriptional activity following 5-aza-20-deoxycytidine treatment. Several
antigen-presentingmachinery components were up-regulated in U251MG cells after demethylating and IFN-g
treatments, suggesting an effect on the up-regulation of HLA-G cell surface expression. Therefore, because of
its role in tumor tolerance, HLA-G found to be expressed in glioblastoma samples should be taken into
consideration in clinical studies on the pathology and in the design of therapeutic strategies to prevent its
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HLA-G Expression in GlioblastomaGlioblastomas are very aggressive brain tumors, exhibiting malignant histologic type (World Health Organization grade
poor response to therapeutic agents. Most of the evasion
mechanisms developed by tumors are related to impairment
of immune system cell function, which should be taken into
account regarding the development of novel immunothera-
peutic approaches. In this respect, human leukocyte antigen-
G (HLA-G) is a pertinent molecule that is involved in
immune tolerance processes and is expressed in numerous
tumors, but has been poorly analyzed in glioblastoma.
HLA-G is a nonclassical HLA class I antigen characterized
by restricted tissue expression in normal conditions,1 low
polymorphism in the HLA-G gene coding region,2 and alter-
native splicing of primary transcript generating membrane-
bound (HLA-G1-G4) and soluble (HLA-G5-G7) isoforms.3,4
HLA-G can inhibit natural killer (NK) and T-cell cytotoxicity
as well as allogeneic proliferation.5e7 These functions are
mediated through the direct binding of HLA-G to the inhib-
itory receptors ILT-2 (LILRB1/CD85j) and ILT-4 (LILRB2/
CD85d)8,9 and KIR2DL4 (CD158d). The latter is expressed
only by NK cells,10 and the KIR2DL4:HLA-G interaction is
still debated.11,12
HLA-G is predominantly produced during pregnancy by
invasive cytotrophoblasts13 andhas alsobeendetected in a few
healthy adult and fetal tissues. On the other hand, HLA-G
expression is induced in several pathological situations, such
as inﬂammatory and autoimmune diseases, transplantation,
and cancer.14 HLA-G expression in tumor lesions was ﬁrst
demonstrated with melanoma. In particular, HLA-G was
expressed in nodular areas of primary melanoma and lymph
nodemetastases fromone patient, but it was not detected in the
healthy skin and regressive area of the primary tumor in the
same patient.15 To date, HLA-G expression has been detected
inmore than 1000 tumor lesions from at least 26 distinct tissue
origins varying from approximately 20% to more than 80% of
the lesions.14 HLA-G can be detected in tumor cells, in tumor-
inﬁltrating cells, or both, being expressed on the cell surface,
secreted, or incorporated into tumor-derived exosomes.15
HLA-G aberrant expression in tumors has thus been sug-
gested to be part of the strategies that tumors use to escape
from the host’s immunosurveillance. In agreement with that,
HLA-Gemediated protection of tumoral cells against NK and
T-cell cytotoxicity was demonstrated in vitro and could
involve trogocytosis.15 Moreover, a correlation between poor
clinical outcomes and HLA-G expression was reported in
several tumoral diseases such as melanoma,16 B cell chronic
lymphocytic leukemia,17 nasopharyngeal carcinoma,18 breast
cancer,19 esophageal squamous cell carcinoma,20 non small
cell lung cancer,21 colorectal tumors,22 and neuroblastoma.23
More recently, the demonstration has been made by means
of a xenotumormodel inmice that theHLA-Gepositive tumor
cell develops and tolerizes the host antitumor immune
response in vivo.24 Collectively, these ﬁndings strongly argue
for HLA-G as a prognostic biomarker.
There are only a few studies investigating HLA-G expres-
sion in glioma, which account for more than 70% of all brain
tumors. Of these, glioblastoma is the most frequent andThe American Journal of Pathology - ajp.amjpathol.orgIV). Despite optimal treatment, the prognosis of glioma
patients is still very poor, as only 9.8% of glioblastoma
patients are still alive at 5 years after diagnosis.25 The
expression and functional activity of HLA-G in glioblastoma
cells was ﬁrst reported byWiendl et al.26 They found HLA-G
expression in four of ﬁve tumor biopsy samples and in some
cultured glioblastoma cell lines; moreover, the expression was
enhanced after INF-g stimulation. Notably, Wiendl et al26
observed that a few HLA-Gepositive cells were sufﬁcient to
inhibit alloreactive lysis ofHLA-Genegative glioma cells and
that the expression of HLA-G rendered glioma cells less
susceptible to alloreactive cytolytic killing. The investigators
thus proposed that HLA-Gedependent suppression of T-cell
responses represents a novel immune escape pathway of
human glioblastoma. More recently, Kren et al27,28 reported
two immunohistochemistry analyses using MEM-G/02
antieHLA-G monoclonal antibody, one analysis performed
in 39 cases of glioblastoma and the other analysis in 26 cases.
Despite the small case number analyzed, HLA-G expression
was observed in 64% of cases in neoplastic astrocytes and in
73% of cases in tumor-inﬁltrating ameboid microglia/macro-
phages. These data again reinforce the importance of investi-
gatingHLA-G in a high number of glioblastoma, aswell as the
mechanisms of its induction and up-regulation.
Interestingly, by comparing HLA-G expression in cultured
cell lines of different tumor types with surgically removed
tumor samples, HLA-G protein expression appeared more
frequent in lesions than in cell lines.29 Therefore, HLA-G
protein expression in vitro may require additional stimulators
that are present in the tumoral microenvironment only. This is
strongly supported by data showing that a primary culture of the
melanoma cell line FONexhibited a high level ofHLA-G1 cell-
surface expression that wasmaintained until passage 40, started
to decrease from passage 66, and then become completely
negative at passage 70.30 In agreement with this observation,
loss of HLA-G1 cell-surface expressionwas reported in in vitro
culture of renal carcinoma cell lines31 and short-term ovarian
carcinoma cell lines.32 Viral and environmental factors, such as
cytokines (granulocyte macrophage-colony stimulating factor,
interferons, IL-10, and leukemia inhibitory factor), hormones
(progesterone, hydrocortisone), stress factors (arsenic, hy-
poxia), nutrient deprivation, and increased acidity have been
associated with HLA-G expression in tumors.1 Nevertheless,
most of them have no direct effect on the induction of HLA-G
gene transcription in tumor cellswhenHLA-Ggene is repressed.
Indeed, we demonstrated that epigenetics is crucial in HLA-G
repression/activation, as DNA demethylating agents and
histone deacetylase inhibitors can reactivate HLA-G gene and
protein expression in malignant cells in vitro.33,34 Finally,
peptide loading and antigen-processing machinery (APM)
components such as low molecular proteasome (LMP)
subunits, LMP2, LMP7, LMP10, transporter associated with
antigen processing (TAP)1, TAP2, calnexin, calreticulin, and
tapasin, aswell asb2-microglobulin (b2-m) are involvedboth in
classical HLA class I and HLA-G cell-surface expression.35,36541
Wastowski et alAPM expression may be modulated in the tumoral context37
and after epigenetic treatments in vitro and thus may also
affect the magnitude of HLA-G expression on the cell
surface.35,36
In the present study, we revaluated the extent of HLA-G
expression in glioblastoma samples and its impact in the
survival rate of patients. We also investigated the impact of
epigenetic processes on the HLA-G gene and APM
component expression in glioma cell lines exposed or not
exposed to IFN-g treatment.
Materials and Methods
Tissues and Patients
This retrospective study included initial specimen surgically
removed from 122 patients with glioblastoma (World Health
Organization grade IV) and no prior treatment to the
craniotomy (Table 1). We used collected archival material
from three different countries: i) Seventy-one glioblastomas
were obtained from patients between 2001 and 2005 in
Odense University Hospital (Denmark); ii) Twenty-seven
glioblastomas were obtained from patients between 2004
and 2008 in Clinics Hospital of Ribeirão Preto of the
University of São Paulo (Brazil); and iii) Ten glioblastomas
were obtained from patients between 2004 and 2008 in
Centre Hospitalier Universitaire Côte de Nacre (Caen,
France). Fresh tissue biopsy samples were ﬁxed in 4%
neutral buffered formalin and parafﬁn embedded. Sections
(3 to 4 mmol/L) were cut on a microtome, stained routinely
with H&E to deﬁne representative tumor regions, and used
for immunohistochemistry (IHC). We also used total RNAs
extracted from 21 glioblastoma biopsy samples obtained
from patients in Caen between 2003 and 2005; seven of
these biopsies were included in the IHC analysis.
Immunohistochemistry
Sections from parafﬁn-embedded specimens were immuno-
stained with MEM-G/02 monoclonal antibody (mAb) (1/50)
that recognizes the free heavy chain of all HLA-G isoforms
(Exbio, Praha, Czech Republic). An isotype-matched antibodyTable 1 Immunohistochemical Analysis of HLA-G Expression in Gliobl
France Denmark
Glioblastomas
HLA-G status Gþ G Gþ
No. of samples (n Z 108) 6 4 40
(60.0%) (40.0%) (56.3%)
Patients
No., male 5 3 28
Age, mean 60.4 68.7 60.3
Range 47e68 63e73 21e78
No., female 1 1 12
Age, mean 70 67 60.2
Range 70 67 43e75
542was used under similar conditions to control nonspeciﬁc
staining. Invasive cytotrophoblast from third trimester human
placenta served as a positive HLA-G protein control.
The reaction product was visualized using the Ultratech
HRP Streptavidin-Biotin Universal Detection System (Immu-
notech-Coulter, Villepinte, France) according to the manu-
facturer’s recommendations. Brieﬂy, after rinsing the sections
in phosphate-buffered saline solution with 0.1% saponin,
endogenous peroxidases were inhibited using 3% hydrogen
peroxide. Samples were initially incubated with speciﬁc or
irrelevant antibodies for 1 hour at room temperature and
subsequently with a solution containing a peroxidase-labeled
polymer conjugated with a goat anti-mouse immunoglobu-
lin for 30 minutes. The diaminobenzidine plus substrate-
chromogen was ﬁnally used to develop antibody ﬁxation
(Dako EnVision-System Peroxidase; Dako, Trappes, France).
All tissues were counterstainedwith hematoxylin (Dako). Two
independent pathologists (E.L.-Z. and B.W.K.) interpreted
HLA-G staining results.
Human Cell Lines and Culture
U251MG and U138MG human glioblastoma cell lines were
provided by Dr. Heinz Wiendl (University of Wuerzburg,
Wuerzburg, Germany) and were initially obtained from
Dr. Nicolas de Tribolet’s laboratory (Centre Hospitalier Uni-
versitaire Vaudois, Lausanne, Switzerland).26 D247MG
glioblastoma cell line was from the laboratory of S.Fe. All
cells were cultured and analyzed in the CEA/Saint-Louis
Hospital laboratory. JEG-3 human choriocarcinoma cell line
(ATCC, Manassas, VA) and M8 melanoma cell line33 were
used as positive and negative controls for HLA-G expression,
respectively. Glioma and choriocarcinoma cell lines were
maintained in Dulbecco’s modiﬁed Eagle’s medium medium
supplemented with Glutamax-I (Invitrogen, Cergy Pontoise,
France), M8 cells were maintained in RPMI-1640 medium
(Sigma-Aldrich, St. Quentin Fallavier, France) supplemented
with L-glutamine (Sigma-Aldrich). All cultures were supple-
mented with 10% heat-inactivated fetal calf serum, 250 mg/L
fungizone (Invitrogen), and 10mg/L gentamicin (Invitrogen).
Cells were routinely tested for absence of contamination with
mycoplasma (plasmoTest, InvivoGen, San Diego CA).astoma Biopsy Samples
Brazil Total
G Gþ G Gþ G
31 19 8 65 43
(43.7%) (70.4%) (29.6%) (60.2%) (39.8%)
19 10 6 43 28
59.8 52.2 48.5 59.7 58.3
37e74 31e67 26e70 21e78 31e74
12 8 2 21 15
64.5 62.7 67 61.3 65
48e78 33e77 65e69 33e77 48e78
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HLA-G Expression in GlioblastomaHLA-G Gene Sequencing and CpG Methylation Analysis
The HLA-G coding region in U251MG, D247MG and
U138MG cell lineswas analyzed for the presence of nonsense
mutations by direct sequencing of PCR products using an
ABI310 Genetic Analyzer (Applied Biosystems, Foster City,
CA) as previously described.38 Methylation status of CpG
sites was performed using a sodium bisulﬁte modiﬁcation of
DNA as previously described,34 with a DNA methylation
detection kit (Biochain, Hayward, CA) according to the
manufacturer’s recommendations. Methylation status of
HLA-G region spanning 443 bp upstream of initiation codon
was analyzed by PCR amplication using the primers
GP328 (50-AAGAGTATAGGAGGATAGGTAAGG-30)
and GP776 (50-AACACCATAACCACCATCCTTAAC-30)
for bisulﬁte-treated DNA and GP327N (50-GAAGAGTAC-
AGGAGGACAGGC-30) and GP717N (50-AGAATGAGT-
CCGGGTGGGTGA-30) for nonebisulﬁte-treated DNA.34
Cell Treatments
The U251MG, D247MG, and U138MG cell lines were
cultured at the initial concentration of 2  106 cells for 24
hours. The culture medium was then changed, and cells
were further cultured in medium (untreated), in medium
supplemented with either 10 mmol/L or 100 mmol/L deme-
thylating drug 5-aza-20-deoxycytidine (5-aza-dC; Sigma-
Aldrich), with 500 U/mL IFN-g (PeproTech, Rocky Hill,
NJ) or with 5-aza-dC and IFN-g combined. Conditions were
maintained until day 5 in most experiments.
Flow Cytometry Analysis
Cells were harvested and washed with PBS containing 0.1%
bovine serum albumin and blocked with human immunoglob-
ulins (Alphaglobin; Grifols, Langen, Germany) for 10 minutes
at 4C. After one washing step, the unlabeled ﬁrst antibody was
added at the ﬁnal concentration. HLA-G cell-surface expression
was evaluated with MEM-G/9 mAb, which recognizes HLA-
G molecules associated with b2-m (Exbio, Prague, Czech
Republic). Isotype control IgG1 was used at the same concen-
tration as the primary antibody. Incubation was done on ice for
30 minutes, followed by two washes. Goat anti-mouse IgG
PE-conjugated F(ab0)2 fragment (5 mg/mL; Sigma-Aldrich) or
dichlorotriazinyl-ﬂuorescein-conjugated F(ab0)2 fragment (10
mg/mL;Dianova,Hamburg,Germany)wereusedas a secondary
antibody. Cells were analyzed using a ﬂow Epics XL cytometer
using Expo32 ADC 1.1C software (Beckman Coulter, Rossy,
France). Speciﬁcﬂuorescence indexes (SFIs)were calculated by
dividing the mean ﬂuorescence obtained with speciﬁc antibody
by mean ﬂuorescence obtained with isotype control antibody.
An SFI value of 1.5 was considered positive.
Quantitative Real-Time RT-PCR analysis
RNAs were withdrawn using RNeasy Mini Kit (Qiagen,
Courtaboeuf, France) according to the manufacturer’sThe American Journal of Pathology - ajp.amjpathol.orgprotocol. A 1 mg quantity of total RNA from each tumor
sample was reverse transcribed at 42C for 1 hour using the
PromegaRT system (Promega, Charbonnieres, France). Total
RNA from cell lines was reverse transcribed using oligo-(dT)
12-18 priming and M-MLV Reverse Transcriptase (Invi-
trogen, Cergy Pontoise, France). Real-time RT-PCR was
performed in triplicate as previously described33 with ABI
Prism 7000 SDS (Applied Biosystems, Courtaboeuf, France)
in a duplex PCRwith 40 ampliﬁcation rounds, using TaqMan
Universal PCR Mix, predeveloped TaqMan assay reagent
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as an
endogenous control, and an HLA-Gespeciﬁc probe located
in exon 5 that targets all HLA-G mRNAs. Quantiﬁcation
was performed relative to amounts of HLA-G transcripts in
HLA-Gepositive JEG-3 using the comparative CTmethod
33:
DCTZCTHLA-GCTGAPDH;DDCTZDCT sampleDCT JEG-3;
relative HLA-G expressionZ 2 DDCT. We analyzed at least
two independent experiments including treated (5-aza-dC,
IFN-g) and untreated glioma cells.
Western Blot Analysis
Untreated and treated cells with 5-aza-dC and/or IFN-g
were collected (5  106) and lysed in lysis buffer (1%
NP40, 50 mmol/L Tris HCl, 150 mmol/L NaCl, 2 mmol/L
EDTA, and 10% glycerol). After centrifugation at 16,000  g
at 4C for 30 minutes, supernatants were transferred to
Eppendorf tubes (Dutscher, Brumath, France). Equal amounts
of cell lysates (50 mg) were normalized by the micro-BCA
assay (Pierce, Rockford, IL) and separated in 10% SDS-
PAGE. All samples were electroblotted onto Hybond-C
extra membrane (Amersham, Les Ulis, France) and blocked
by incubation with Tris-buffered saline (TBS) 5% nonfat dry
milk for 30 minutes. After blocking, membranes were washed
three times in TBS solution containing 0.2% Tween-20, then
probed with the corresponding mAb overnight at 4C and
washed three times in TBS containing 0.2% Tween-20. The
membranes were incubated for 30 minutes at room tempera-
ture with peroxidase-conjugated goat anti-mouse IgG directed
against heavy and light chains (H&L) and washed three times
in TBS containing 0.2% Tween-20. The membranes were
treated with West Pico Chemiluminescent Substrate (Thermo
Scientiﬁc, Rockford, IL) for 1 minute and exposed to Kodak
Biomax MR ﬁlm. The cell line JEG-3 was used as a positive
HLA-G control.
The following mAbs were used in Western blotting: an
antitubulin antibody for internal control (Sigma-Aldrich);
the anti-pan HLA-G 4H84 (mouse IgG1; provided by
Michael McMaster, University of California, San Fran-
cisco, CA); the b2m-speciﬁc mAb L36839; the LMP2-
speciﬁc mAb SY-1; the LMP7-speciﬁc mAb HB-2; the
LMP10-speciﬁc mAb TO-6; the TAP1-speciﬁc mAb
NOB-1; the TAP2-speciﬁc mAb NOB-2; the calnexin-
speciﬁc mAb TO-5; the calreticulin-speciﬁc mAb TO-11;
the ERp57-speciﬁc mAb TO-2, and the tapasin-speciﬁc
mAb TO-3 were developed and characterized as543
Wastowski et aldescribed elsewhere.40e42 The mAbs were puriﬁed from
ascitic ﬂuid by sequential precipitation with ammonium
sulphate and caprylic acid.43 The purity of mAb prepara-
tions was assessed by SDS-PAGE. The activity of the
mAb preparations was monitored by testing with a
lymphoid cell lysate in Western blotting. Intensities of the
bands were analyzed using AlphaEaseFC software version
3.1.2 (FluorChem 8800 Digital Imaging; Alpha Innotech.,
San Leandro, CA).
Chromatin Immunoprecipitation
Chromatin immunoprecipitation (ChIP) assays were per-
formed as previously described34 with antiephospho(S10)-
acetyl(K14)-histone H3 (07-081; Upstate, Lake Placid,
NY), antieacetyl(K18)-histone H3 (07-354, Upstate), and
antieRNA polymerase II (sc-899 X; Santa Cruz Biotech-
nology, Santa Cruz, CA). Brieﬂy, cell line cultures were
exposed to formaldehyde for cross-linking proteins and
DNA together, followed by chromatin sonication into
pieces of approximately 300 to 500 bp. Cross-linked
chromatin was immunoprecipitated with either no anti-
body () or the indicated antibody. The antibody-protein-
DNA complexes were puriﬁed using beads coupled to
protein Aesepharose (Sigma-Aldrich). The DNA was iso-
lated from the complexes using a combination of heat to
reverse cross-linking, RNase, and proteases and was then
puriﬁed using phenol extraction and ethanol precipitation.
The ﬁnal DNAs from ChIP and input chromatin (PCR
control) were then used as templates in PCR using primer
set 187 forward (50-CCCGCGTTGGGGATTCTCTC-30) /
þ4 reverse (50-AGAGGGTTCGGGGCGCCATGAC-30)
speciﬁc for the HLA-G gene proximal promoter and primer
set 1089 F (50-CCCTTTGTGACTTCAAGAAC-30), and5441252 R (50-AAGTTATAGCTCAGTGGACC-30) speciﬁc
for the HLA-G 30 untranslated region (30UTR).
Statistical Analysis
We used Prism version 5.0 (GraphPad Software, San Diego,
CA) and the nonparametric U-test for comparison of values
obtained by real-time PCR analysis. Data are presented as
means  SEM for at least three independent experiments.
Survival analysis was performed using the log-rank test and
graphical representation was performed by Kaplan-Meier.
The analysis took into account patients who died of the
tumor excluding other reasons (data were validated from the
hospital charts and death certiﬁcate). Signiﬁcancewas deﬁned
as a P < 0.05 at a conﬁdence interval of 95%.
Results
HLA-G Is Frequently Expressed in Glioblastoma Biopsy
Samples
To evaluate the extent of HLA-G protein expression in glio-
blastoma lesions, we performed a multicentric IHC analysis
of parafﬁn-embedded biopsy sections of 108 glioblastoma
lesions (World Health Organization grade IV) from French,
Danish, and Brazilian patients using the antieHLA-G
monoclonal antibody MEM-G/02, which recognize all HLA-
G isoforms. Results in Table 1 show that HLA-Gwas detected
in 60.2% of cases, ranging from 56.3% in Danish patients to
70.4% in Brazilian patients. Therefore, the majority of glio-
blastoma specimens are HLA-G positive, whatever the
geographic origin of patients. No correlation between age or
sex and HLA-G expression could be established. In most
cases, HLA-G expression was observed in astrocyteFigure 1 HLA-G expression in parafﬁn-
embedded sections of glioblastoma. A: Invasive
cytotrophoblast from third trimester human
placenta served as a HLA-Gepositive control
immunostained with the antieHLA-Gespeciﬁc
MEM-G/02 monoclonal antibody (mAb) (all
isoforms are recognized). BeD: Representative
HLA-Gepositive glioblastoma specimens immu-
nostained with MEM-G/02 mAb. Arrows indicate
gemistocytic tumor cells in B, giant tumor cells in
C, and macrophages in D. E and F: Representative
HLA-Genegative glioblastoma specimens immu-
nostained with MEM-G/02 mAb. Scale bars: 50 mm
(A), 20 mm. (BeF). Original magniﬁcation, 40.
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HLA-G Expression in Glioblastomagemistocytics but also was observed in inﬂammatory inﬁl-
trating cells (Figure 1).
HLA-G transcriptional activity was investigated on 21
glioblastoma biopsy samples from French patients using
quantitative real-time RT-PCR; seven of the samples (G3,
G14, G17, G18, G19, G20, and G21) were also included in
the IHC analysis. By comparing glioblastoma HLA-G
transcriptional activity with that of HLA-Gepositive cell
line JEG-3 and HLA-Genegative cell lines U251 and M8,
we observed that with the exception of the G7 biopsy
sample, levels of HLA-G gene transcription were clearly
higher (at least ninefold) in glioblastoma biopsy samples
than in HLA-Genegative cells (Figure 2). The highest
amounts of HLA-G mRNA were found in G1, G12, G16,
and G19 samples corresponding to w 1 in 50 of JEG-3
HLA-G mRNA. It is of note that HLA-G protein expres-
sion analyzed by IHC was detected only in G17, G19, G20,
and G21, whereas G3, G14, and G18 were HLA-G negative,
suggesting that post-transcriptional mechanisms participate
in the observed HLA-G protein expression.
Lack of HLA-G Expression May Be a Pronostic Indicator
of Long-Term Survival Rate
In an effort to assess the impact of HLA-G protein expres-
sion on the survival rate of patients with glioblastoma, we
generated Kaplan-Meier survival curves using available data
in 106 patients (26 Brazilian, 9 French, and 71 Danish
patients). We excluded one patient (HLA-Genegative)
who was still alive at the time of the study, and one patient
(HLA-Gepositive, 6-month survival) who died of pulmo-
nary embolism rather than glioblastoma. The survival time of
104 patients from the date of craniotomy varied between 1
and 70 months (one patient with 70-month survival). HLA-G
expression was not signiﬁcantly correlated with a lower
survival rate of an HLA-Gepositive patient compared with
HLA-Genegative patients (mean survival rate, 8 months)
(Figure 3A). To further analyze the impact of HLA-G
expression in patients with long-term survival, we gradu-
ally analyzed patients having a survival of more than 8
months and found no signiﬁcant association before 15
months. After 15 months, it was possible to observe thatThe American Journal of Pathology - ajp.amjpathol.orgHLA-Genegative patients were still alive 7 months longer
than HLA-Gepositive patients (P Z 0.04) (Figure 3B).
HLA-G Induction in Glioma Cells Requires DNA
Demethylation and Is Enhanced by Incubation with
IFN-g
To investigate the mechanisms underlying the induction of
HLA-G expression in glioblastoma cells, we used the
human glioma cell lines U251MG, U138MG, and D247MG
as models for in vitro studies. We did not detect any
signiﬁcant HLA-G mRNA amounts using quantitative real-
time RT-PCR or protein expression using Western blot and
ﬂow cytometry, even after incubation with IFN-g (Figures 4
and 5). Interestingly, sodium bisulﬁte genomic sequencing
performed with U251MG cells showed that 18 CpG sites are
methylated among the 19 CpG sites located within the
HLA-G gene fragment spanning 443 bp upstream to ATG
(Supplemental Figure S1). Therefore, having previously
demonstrated that DNA demethylation at the HLA-G locus
induced HLA-G gene expression, we cultured the three cell
lines in medium supplemented with the demethylating agent
5-aza-dC (100 mmol/L) and/or IFN-g (500 U/mL). As ex-
pected, HLA-G mRNA was up-regulated in all cell lines
treated with 5-aza-dC and 5-aza-dC/IFN-g compared with
cells in medium alone (untreated). In addition, levels of
HLA-G transcripts were increased in the three cell lines after
combined treatments with 5-aza-dC/IFN-g compared with
5-aza-dC alone (Figure 4). It is noteworthy that the highest
amounts of HLA-G mRNA were observed in the U251MG
cell line after 5-aza-dC treatment (U251MG  U138MG:
PZ 0.04; U251MG  D247MG: PZ 0.01; U-test; nZ 3)
and after 5-aza-dC/INF-g treatment (U251MG  U138MG,
P Z 0.05; U251MG  D247MG, P Z 0.05; U-test;
n Z 3). We performed an additional experiment with
U251MG cells in which 5-aza-dC and IFN-g were removed
from the growth medium after 5 days of treatment. We
analyzed HLA-G transcription at day 5 after 5-aza-dC and
IFN-g treatments and at days 6, 7, and 8 of cell culture
without treatment. We observed that the induced HLA-G
transcriptional activity was still maintained, even in the
absence of treatment (Supplemental Figure S2).Figure 2 HLA-G transcriptional activity in 21
glioblastoma biopsy samples (G1 to G21). Results
of real-time RT-PCR performed twice (each in
triplicate) are presented, with two distinct sticks
(mean of triplicates) for each sample, except G7
(only one experiment). Results are compared to
the HLA-G mRNA expression in HLA-Gepositive
choriocarcinoma JEG-3 cells (assigned a value of
1) and HLA-Genegative cell lines melanoma M8
and glioblastoma U251MG. Glioblastoma speci-
mens studied in IHC are underlined. Plus (þ) and
minus () signs indicate positive and negative
HLA-G protein expression (IHC), respectively.
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Figure 3 Survival analysis of 104 patients with glioblastoma either
expressing or not expressing HLA-G protein at the tumor site (Kaplan-Meier
survival curves). A: Survival time of 104 patients from the date of crani-
otomy. The median survival rate is 8 months for HLA-Gepositive and
HLA-Genegative patients. B: Survival time of 23 patients after 15 months
from the date of craniotomy. HLA-Genegative patients are still alive
7 months longer than HLA-Gepositive patients (P Z 0.04).
Wastowski et alThen, to test whether the induced HLA-G transcripts were
translated into proteins, we performed Western blot assays
using antieHLA-G 4H84 mAb. Figure 5A presents
a representative result from four independent experiments,
showing that the incubation with IFN-g alone had noU
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Figure 4 Induction of HLA-G gene transcription in HLA-Genegative glioma c
U/mL). Real-time RT-PCRs (performed in triplicate for each experiment) targeting a
and D247MG), either untreated (UT) or treated with 5-aza-dC alone, 5-aza-dC and I
HLA-G mRNA levels relative to mRNA expression in HLA-Gepositive JEG-3 chorioca
at least three independent experiments. Statistical analysis was performed using
546detectable effect on the HLA-G protein expression in the
three cell lines analyzed. Cell treatment with 100 mmol/L
5-aza-dC alone induced HLA-G protein expression in
U251MG, but not in D247MG and U138MG cell lines. In
U251MG cells, a 2.4-fold increase in HLA-G expression
was observed after incubation with 5-aza-dC and IFN-g
combined (mean 1.95-fold increase; SEMZ 0.185; nZ 4),
and was still not detectable on D247MG and U138MG cells.
The complete coding sequence analysis of the HLA-G
alleles in the three cell lines did not reveal any nonsense
mutation (data not shown).
On the other hand, ﬂow cytometry analysis of the cell
lines stained with the antieHLA-G mAb MEM/G9 revealed
a weak staining of the cell membrane of U251MG cells after
a 24-hour incubation (data not shown); the staining
progressively increased by prolonging the incubation to 120
hours (SFIZ 1.5 was observed in two of three experiments)
(Figure 5B). In agreement with the results of QRT-PCR and
western blot experiments, the incubation with 5-aza-dC and
IFN-g increased the level of HLA-G expression on the cell
membrane of U251MG cells (SFIZ 3; mean SFIZ 2.9 of
three independent experiments) (Figure 4B) compared to
cells incubated with 5-aza-dC alone. Moreover, we
observed that the HLA-G expression was maintained in
U251 treated cultures for at least 15 days (data not shown).
HLA-G Expression in Glioma Cells Is Associated with
Chromatin Remodeling at the HLA-G Promoter and the
Modulation of APM Components upon Treatment
To identify elements inﬂuencing HLA-G gene induction and
cell surface expression, we ﬁrst examined chromatin
modiﬁcations at the proximal HLA-G promoter region in
untreated U251MG, D247MG, and U138MG cell lines. By
ChIP, we observed that S10 phosphorylated K14-acetylated
H3 histone, a pattern which is often associated with gene
activation, is found only in U251MG cells (Figure 6A).
Next, we used ChIP assays to explore the H3-K18 acety-
lation, another hallmark of gene activation, at the HLA-GD247MG
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Figure 5 Induction and up-regulation of HLA-G protein expression in
U251MG glioma cells upon 5-aza-dC and 5-aza-dC/IFN-g treatments
(day 5). U251MG, D247MG, and U138MG cells were either untreated (UT) or
treated with 5-aza-dC alone, 5-aza-dC and IFN-g combined, or IFN-g alone.
A: Representative Western blots performed with the antieHLA-G 4H84 and
anti-tubulin antibodies (four independent experiments). A value of 1 is
assigned to the HLA-G protein level in 5-aza-dCetreated cells. B: Repre-
sentative ﬂow cytometry analysis was performed with the antieHLA-G
MEM-G/9 antibody (dark) and IgG1 isotype control (three independent
experiments with similar results). Numbers in the upper right corner of each
box indicate SFI values. An SFI value of 1.5 was considered positive. U251MG U138MG D247MG
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Figure 6 Differential pattern of H3 phospho-acetylation at the HLA-G
locus in glioma cell lines U251MG, U138MG, and D247MG. Representative
ChIP experiments are performed with no antibody (), antibodies directed
against H3-S10P-K14Ac (A), H3-K18Ac (BeD), and anti-RNApolymerase II (C
and D). BeD: HLA-G promoter and 30 untranslated region (30UTR) modiﬁca-
tions in U251MG are compared with those of choriocarcinoma cell line JEG-3,
which exhibits high levels of HLA-G transcripts.187 F /þ4R andþ 1089F /
þ 1252R indicate primer set used for PCR targeting proximal HLA-G promoter
and HLA-G 30 UTR, respectively; input is input chromatin used as PCR control.
HLA-G Expression in Glioblastomagene promoter and 30 untranslated region in U251MG and
HLA-Gepositive JEG-3 cells, and found H3 acetylation in
both cell lines (Figure 6, B and D). On the other hand, ChIP
assays targeting RNA pol II was positive only at the HLA-G
gene promoter in JEG-3 (Figure 6, C and D), a result in
agreement with the very low presence or the absence of
HLA-G transcriptional activity observed in untreated
U251MG cells (Figure 4). Therefore, the chromatin struc-
ture at the HLA-G promoter in U251MG cells exhibits
a pattern that is compatible with HLA-G transcription, but
the structure is still not accessible to RNA pol II when cells
are cultured in medium alone.
Next, we evaluated the effect of 5-aza-dC and IFN-g
treatments on the modulation of accessory proteins that are
involved both in classical HLA class I and HLA-G cell
surface expression. Calnexin, calreticulin, TAP-1, TAP-2,
tapasin, Erp57, proteasome subunits LMP-2, -7, -10, and
b2-m expressions were analyzed by Western blots of protein
extracts of U251MG cells either exposed or not exposed to
5-aza-dC and IFN-g for 4 or 5 days (Figure 7). The
demethylating agent, either alone or combined with IFN-g,
had a slight effect on the up-regulation of APM components
and b2-m except calreticulin. On the other hand, although
IFN-g alone had no effect on the HLA-G protein expres-
sion, IFN-g increased almost all APM components and
b2-m, with stronger effect in comparison with 5-aza-dC. In
particular, mean values from two independent experimentsThe American Journal of Pathology - ajp.amjpathol.orgrevealed a 1.8-fold increase in b2-m expression, a twofold
increase in TAP-1 expression, and 3.9- and 4.7-fold
increases in LMP-2 and LMP-7 expression, respectively,
in U251MG cells treated with IFN-g compared with cells
treated with 5-aza-dC alone (data not shown). A combina-
tion of treatments had no strong additive effect on APM
component expression (Figure 7).
Discussion
Despite better knowledge of the molecular mechanisms
involved in glioma phenotype and introduction of the new
treatment with radiation and temozolomide in 2005, the
median survival time for patients continues to be very poor.
Glioblastoma appears to beneﬁt from the central nervous
system, which has been considered an immunologically
privileged site. In fact, T lymphocytes and antigen presenting547
Figure 7 APM components and b2-m up-
regulation in U251MG glioma cell line upon
5-aza-dC and IFN-g treatments. Representative
Western blots are presented (at least two inde-
pendent experiments). Protein extracts (50 mg) are
from U251MG cells either untreated (UT) or treated
with 5-aza-dC alone, 5-aza-dC/IFN-g combined,
and IFN-g alone. Results obtained from the same
gel are framed. Quantitative variations are indi-
cated; a value of 1 is assigned to the amount of
APM component in untreated cells or to the
amount of HLA-G expression in cells treated with
5-aza-dC alone.
Wastowski et alcells pass through the central nervous system during path-
ologic conditions such as neurodegenerative diseases44 and
glioma.45 Microglia, an important portion of resident central
nervous system cells, exhibits the ability to generate
signiﬁcant innate and adaptive immune responses after
infectious and traumatic stimuli. Indeed, under pathological
conditions, microglia express the molecular machinery
required to present antigen and acquire the potential to
interact with T cells in an antigen-speciﬁc manner.46
Therefore, the brain should be viewed as an immunologi-
cally quiescent site, and the poor prognosis for glioblastoma
may be due in part to mechanisms that promote tumor
tolerance and immune suppression.47
Previous studies47 have highlighted that glioblastoma may
use multiple immune evasion strategies such as secretion of
immunosuppressive cytokines and factors (prostaglandin E2,
transforming growth factor b, vascular endothelial growth
factor, and IL-10), and impairment of adhesive effectors to
extracellular matrix proteins. Other mechanisms, including
glioblastoma up-regulation of B7 homologue 148 and STAT-
3,49 have been proposed in inhibiting allogenic T-cell acti-
vation and/or modifying cytokine proﬁle expression toward
Th2. With regard to classical HLA class I molecules, a defect
was previously reported in only w 50% of glioblastomas
tested and was signiﬁcantly correlated with astrocytic tumor
grade, although, no correlation between HLA class I expres-
sion and survival was found.37 Interestingly, an observation
was made that APM alterations may occur in tumor cells
expressing normal levels of HLA class I molecules. There-
fore, it was proposed that production of peptide-free HLA
molecules would affect immune recognition of tumors cells
by T cells and promote HLA class I inhibition of NK cells.50
Indeed, LMP2, TAP1, and b2-m were previously demon-
strated to be down-regulated in high-grade astrocytomas,50
a result that we conﬁrmed in the present study (Figure 7). In
addition, tapasin down-regulation was observed associated548with HLA class I antigen down-regulation as well as tumor
grade, although not signiﬁcant (possibly due to sample
size).37 The present work shows that nonclassical HLA-G is
frequently transcribed in glioblastoma and the protein
expressed in w 60.2% of cases (n Z 108), and may be
induced in HLA class Iepositive cell lines. Despite having
studied smaller patient cohorts, several reports strongly
support our ﬁnding : i) HLA-G mRNA expression was
detected in four of 12 tested glioma cell lines26; ii) tran-
scriptomic microarray performed with total mRNA from 20
glioblastoma specimens detected 12 tumors with signiﬁcant
HLA-G mRNA expression compared with a pool of non-
neoplastic brain samples51; and iii) immunohistochemical
analyses performed with different antieHLA-G mAb
revealed that HLA-G protein is expressed in 75% (nZ 4),26
73% (n Z 26),28 and 64% (n Z 39),27 of the tested glio-
blastoma samples, both in tumor cells and in inﬁltrating
microglia/macrophages. HLA-G expression in the latter cells
thus makes them behave as regulatory cells involved in
immune suppression. Therefore, even if the mechanism
involving classical HLA class I molecules is likely to partic-
ipate in glioma escape from the immune system, HLA-G
would exert its immunosuppressive properties both in the
absence and presence of classical HLA class-I molecules.15
Interestingly, recent reports52,53 have shown that ILT-4
(LILRB2/CD85d) can recognize the b2M-free HLA-G, but
ILT-2 (LILRB1/CD85j) cannot. Therefore, despite down-
regulation of b2-m in glioblastoma, HLA-G would be
capable of conferring an inhibitory effect selectively on
ILT-4eexpressing cells, such as antigen-presenting cells. A
previous study27 performed with 39 cases reported that the
expression of HLA-G in glioblastoma cells was prognosti-
cally neutral. By studying a larger number of cases, we also
found that HLA-G expression in tumor samples with no prior
treatments was prognostically neutral. However, we cannot
exclude the possibility that therapeutic treatments could haveajp.amjpathol.org - The American Journal of Pathology
HLA-G Expression in Glioblastomamodulated HLA-G expression. One possibility is that HLA-G
has been induced in some permissive tumors, thus reducing
time survival of some patients whowere diagnosed asHLA-G
negative before treatment. Interestingly, we found that the
absence of HLA-G expression in glioblastoma at the time of
craniotomy was associated with a favorable outcome in
patients after 15 months of survival. This is in agreement with
several studies describing a positive correlation between
HLA-G expression in cancer and shortened survival of
patients,54 and suggests a potential role of HLA-G participa-
tion in the down-regulation of anti-glioblastoma immune
responses.55
Focusing on the HLA-G expression in glioblastoma and
consequently the possible effect in tumor escape, we thus
investigated mechanisms that could induce it. Considering
the literature data in the ﬁeld, the up-regulation of HLA-G in
glioblastoma is likely to involve the interaction of tumor
microenvironment such as hypoxia, immunosuppressive
molecules, and therapeutic treatments, with HLA-G alleles
of the patients.1,56 Indeed, the HLA-G gene polymorphism is
frequent in 50 and 30 untranslated regions and may affect the
binding of transcription factors and miRNAs,57,58 thus
providing a tangible explanation for its participation in the
absence or in the low level of HLA-G protein expression in
almost 40% of the tested biopsy samples. Moreover, by
analyzing HLA-G mRNA levels in 21 glioblastoma biopsy
samples, we observed quantitative variations, even though
almost all samples exhibited HLA-G transcriptional activity.
However, amounts of HLA-G transcripts were lower than
those of choriocarcinoma JEG-3 cell line, probably due to
tumoral tissue heterogeneity. Finally, regarding the HLA-G
expressed in inﬁltrating microglia/macrophages, it is
tempting to speculate that it might reﬂect a tumor-derived
HLA-G acquisition through trogocytosis, a mechanism
that has been previously observed in vitro.15
Here, we investigated the impact of 5-aza-dC and IFN-g
treatments. There is evidence that DNA hypermethylation is
detected in 87% of glioblastoma lesions.59 Accordingly, to
develop tumor antigen-speciﬁc active immunotherapy, it has
been proposed to up-regulate melanoma associated antigen
(MAGE)1 by 5-aza-dC treatment combined with a strategy
to up-regulate major histocompatibility complex levels by
IFN-g to augment tumor cell recognition by tumor antigen-
speciﬁc T cells.60 5-aza-dC treatment was also proposed as
a drug candidate to up-regulate human telomerase reverse
transcriptase in glioma to reduce telomerase expression.61 In
agreement with previous observations in several tumor cell
types,33,34 here we demonstrate that HLA-G promoter region
is methylated in U251MG cells and that HLA-G transcrip-
tional expression in glioma cells is always induced by 5-aza-
dC treatment. Methylation/demethylation processes are thus
key events in the observed HLA-G transcriptional up-
regulation in glioma cells. Interestingly, levels of HLA-G
mRNAs were enhanced by combining 5-aza-dC with IFN-g
treatment, whereas as previously reported for NK and NK-
like cells,62 IFN-g alone had only a slight effect on theThe American Journal of Pathology - ajp.amjpathol.orginduction of HLA-G gene transcriptional activity, sug-
gesting that IFN-g probably required HLA-G gene deme-
thylation before having an effect. The cell lines in the
present study were studied elsewhere,26 showing a consti-
tutive HLA-G transcription only in U251MG and D247MG
cells, whereas HLA-G transcription became detectable in
U138MG cells after IFN-g treatment. In addition, HLA-G
was not detectable on the cell membrane and was induced
with IFN-g at the cell surface of D247MG and U138MG,
suggesting that HLA-G stability is not affected in these
cells. It is noteworthy that, by studying these cell lines in
the CEA/Saint-Louis Hospital laboratory, we did not ﬁnd
such HLA-G expression supporting that environmental
conditions are of crucial importance in the induction of
HLA-G expression and its maintenance in culture. Besides,
our ﬁndings did not support the induction of high levels of
HLA-G mRNA in HLA-Genegative glioma cells after
IFN-g treatment alone.26 Nonetheless, HLA-G mRNA
levels were assessed by Northern blot analysis, a less
sensitive methodology that would not allow detection of
low level HLA-G mRNA in untreated cells, and thus could
explain such apparently contradictory results.
Furthermore, we showed that U251MG cells exhibited
better efﬁciency in HLA-G gene induction upon 5-aza-dC
treatment than U138MG and D247MG cells. It is noteworthy
that doubly modiﬁed H3-S10PK14Ac was observed only at
the proximal promoter of U251MG. This dual modiﬁcation is
known to allow interaction of 14-3-3 proteins, which are
important factors for mediating the switch from transcrip-
tional repressive to active chromatin in vivo, and thus induc-
tion of many genes. Interestingly, previous studies found that
strong 14-3-3 protein expressionwas observed and associated
with tumor genesis and progression in glioma.63 In addition,
we revealed H3-K18Ac post-transcriptional modiﬁcation at
the HLA-G promoter in U251MG cells, a chromatin pattern
again associated with gene activation. Altogether, these
chromatin modiﬁcations strongly suggest that the amplitude
ofHLA-G gene activation in glioblastoma cells after 5-aza-dC
treatment is dependent on the permissive (or nonpermissive)
statute of the chromatin at the HLA-G locus. Accordingly,
further exploration in glioblastoma biopsy samples either
expressing or not expressing HLA-G is justiﬁed and currently
under investigation.
As previously demonstrated for JAR, Raji, and LCL
721.221 cell lines,33 5-aza-dC treatment of U251MG cells
also directly induced the expression of HLA-G protein and
its expression at the cell surface (Figure 4B). Conversely,
HLA-G protein induction was not observed in U138MG and
D247MG cells. Because we did not ﬁnd any nonsense
mutations in the coding region of the HLA-G alleles, we can
hypothesize this result to be due either to lower levels of
induced HLA-G mRNA compared to U251MG cells or
to other regulatory mechanisms acting at the post-
transcriptional level, such as miRNAs.58,64 In agreement,
by investigating RNA and protein on the same tissue
specimen (Figure 2), we observed that although HLA-G549
Wastowski et altranscriptional activity was observed in all samples, HLA-G
protein was detected only in four of seven samples.
It is noteworthy that the modulation of the expression of
APM components showed in the present study is also
a pertinent parameter to consider in the induction of HLA-G
cell-surface expression. The effect of 5-aza-dC treatment on
APM components was previously investigated on the
melanoma cell line OGM-1A, showing TAP1, TAP2,
LMP2, and tapasin increase.36 In the present work, we
observed the up-regulation of some APM components but
the increase was small compared with the effect of IFN-g. In
particular, reduced expression of the TAP1 molecule has
been reported in glioma cell lines and, in agreement with our
data, was up-regulated upon IFN-g treatment.65 In addition,
we noted that calreticulin expression was not up-regulated
with both treatments. Interestingly, it has been reported
that in neither the untreated nor treated OCM-1A cells,
calreticulin expression was detected. Moreover HLA-G cell
surface expression in 5-aza-dCetreated OCM-1A mela-
noma cells was much less than that on the HLA-Gepositive
JEG-3 cell, whereas a similar amount of total HLA-G was
observed. Calreticulin was thus hypothesized to be critical
for levels of HLA-G cell surface expression in OCM-1A,36
and therefore could be involved in the level of HLA-G cell
surface expression in U251MG cells.
In conclusion, taken together, our data strongly suggest that
new therapeutic strategies such us immunotherapy for glioma
need to take into account antigens constitutively expressed by
cells in the tumor lesion and their impact on glioma-associated
immune suppression and invasion. Indeed, thedown-regulation
of someAPM components in glioblastomamight not affect the
expression of all HLA-G isoforms and HLA-G cell surface
expression could be induced and/or up-regulated after treat-
ments in permissive cells. The lack of HLA-G expression in
some glioblastomas and the variability of HLA-G induction
in vitro among cell lines also suggest that the HLA-G gene
polymorphism56 should be taken into consideration, as it can
affect the activity of transcription factors66 and miRNA
binding.58,67 Therefore, it could be very useful to decide HLA-
G typing in favor of or against therapeutic treatments using
5-aza-dC and IFN-g.
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